Using clinical and economic evidence to infrom local decision making in cancer care

Funded Activity Summary

Medicines used to treat cancer often come with a high price tag. Many countries, including Australia, are no longer able to provide free access to all medicines. For this reason, patients and their families, public hospitals and private health insurers are often asked to pay for these treatments. Currently, health professionals and patients are ill-equipped to make informed treatment choices, since both cost and efficacy must be considered. Our proposed research will address this important gap in current knowledge. We will use a unique web-based resource (Cancer Institute NSW Standard Cancer Treatment Program; CI-SCaT) to communicate the economic evidence needed to make informed decisions about cancer treatments. Our project will provide public access to information about the effectiveness and costs of cancer drugs. This is a world first. CI-SCaT is already the main vehicle of communication about cancer drug treatments in NSW and is widely used by cancer health professionals and patients to inform point-of-care decisions. Our project we will also identify the factors which influence the ability of cancer treatment centres to make best use of their drug budgets. By achieving this goal, we hope to demonstrate how to best use scarce resources for the benefit of all cancer patients.

Funded Activity Details

Start Date: 01-01-2007

End Date: 01-01-2012

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $1,836,745.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Public Health and Health Services

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cancer treatment | Health care utilization | Health outcomes | Therapeutics | cost effectiveness

Related Links